Perrigo/$PRGO
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Perrigo
Perrigo is a pure-play consumer healthcare product manufacturer and distributor. In North America (two-thirds of total sales), the firm's product mix centers on private-label consumer health goods sold to major retailers such as Walmart, Amazon.com, Costco, and CVS. It plays in a number of over-the-counter categories including pain, skincare, women's health, and nutrition. Perrigo also competes in Europe, Australia, and parts of Asia, where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
- Ticker
- $PRGO
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 8,100
- Headquarters
- Dublin, Ireland
- Website
- www.perrigo.com
Perrigo Metrics
BasicAdvanced
$2.4B
-
-$12.72
0.69
$1.16
6.85%
Price and volume
Market cap
$2.4B
Beta
0.69
52-week high
$17.07
52-week low
$9.23
Average daily volume
2.4M
Dividend rate
$1.16
Financial strength
Current ratio
2.354
Quick ratio
1.1
Long term debt to equity
1.404
Total debt to equity
1.35
Interest coverage (TTM)
1.05%
Profitability
EBITDA (TTM)
560
Gross margin (TTM)
32.85%
Net profit margin (TTM)
-43.27%
Operating margin (TTM)
5.53%
Effective tax rate (TTM)
-4.67%
Revenue per employee (TTM)
$500,000
Management effectiveness
Return on assets (TTM)
1.61%
Return on equity (TTM)
-50.25%
Valuation
Price to revenue (TTM)
0.576
Price to book
0.96
Price to tangible book (TTM)
-1.69
Price to free cash flow (TTM)
13.565
Free cash flow yield (TTM)
7.37%
Free cash flow per share (TTM)
1.249
Dividend yield (TTM)
6.85%
Forward dividend yield
6.85%
Growth
Revenue change (TTM)
-4.47%
Earnings per share change (TTM)
3,289.41%
3-year revenue growth (CAGR)
-4.21%
10-year revenue growth (CAGR)
-2.57%
3-year earnings per share growth (CAGR)
648.30%
10-year earnings per share growth (CAGR)
-4.43%
3-year dividend per share growth (CAGR)
2.44%
10-year dividend per share growth (CAGR)
7.55%
What the Analysts think about Perrigo
Analyst ratings (Buy, Hold, Sell) for Perrigo stock.
Analyst projections of the future price of Perrigo stock.
Bulls say / Bears say
Perrigo gained 30 basis points of US store-brand OTC share in the quarter, while its key European brands grew value sales by 6.5% and gained 80 basis points. That suggests the company is winning customers even in a soft market. (Perrigo)
Core sales declines eased from 8.3% in the first quarter to 1.7% in the third, while adjusted operating margin rose from 12.8% to 14.3%. If this operational improvement continues, it could help restore earnings momentum. (The Motley Fool)
The agreed Infant Formula sale would focus Perrigo on consumer self-care and is expected to improve margins and reduce future capital spending. The deal offers up to $175 million, although only $40 million is upfront and the remainder depends on future milestones. (Perrigo)
Management updated its 2026 outlook to reflect cautious retailer inventory positioning ahead of cough-and-cold season and ongoing weakness in Europe. Those pressures point to uncertain demand and could keep sales under strain. (Perrigo)
Core adjusted gross margin fell 140 basis points to 37.9%, and adjusted EPS dropped 9% year on year to $0.61. Lower volumes and an unfavourable sales mix are weighing on profitability. (Perrigo)
Perrigo had $3.3 billion of debt against $437 million of cash at quarter-end, and management expects year-end net leverage of about four times adjusted EBITDA. That leaves the company with limited financial flexibility if its recovery stalls. (Perrigo)
Data summarised monthly by Lightyear AI. Last updated on 9 Nov 2026.
Perrigo Financial Performance
Revenues and expenses
Perrigo Earnings Performance
Company profitability
Upcoming events
Perrigo News
AllArticlesVideos
Funds containing Perrigo
Fund name | Fund size | $PRGO weighting |
|---|---|---|
iShares S&P SmallCap 600$IDP6 | $2.5B | 0.13% |
iShares S&P Small Cap 600£ISP6 | $2.5B | 0.13% |
SPDR MSCI USA Small Cap Value Weighted$USSC | $1.1B | 0.11% |
SPDR S&P US Dividend Aristocrats€SPYD | $3.9B | 0.08% |
SPDR S&P US Dividend Aristocrats£USDV | $3.9B | 0.08% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
